Suggested Readings

Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the southern United States.

Colasanti J, Sumitani J, Mehta CC, et al. Open Forum Infect Dis. 2018;5(6):ofy104.

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.

Cutrell AG, Schapiro JM, Perno CF, et al. AIDS. 2021;35(9):1333-1342.

Phase 3 study of ibalizumab for multidrug-resistant HIV-1.

Emu B, Fessel J, Schrader S, et al. N Engl J Med 2018;379(7):645-654.

Linkage and antiretroviral therapy within 72 hours at a Federally Qualified Health Center in New Orleans.

Halperin J, Butler I, Conner K, et al. AIDS Patient Care STDS. 2018;32(2):39-41.

Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.

Hardy WD, Gulick RM, Mayer H, et al. J Acquir Immune Defic Syndr. 2010;55(5):558-564.

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.

Lataillade M, Lalezari JP, Kozal M, et al. Lancet HIV. 2020;7(11):e740-e751. 

Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.

Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.  

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

Overton ET, Richmond G, Rizzardini G, et al. Lancet. 2021;396(10267):1994-2005.

Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection.

Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. N Engl J Med. 2022;386(19):1793-1803.

Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV.

Sterman FL, Lalezari JP, Kowalczyk UM, et al. AIDS. 2023;37(7):1057-1064.

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.

Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.

Linked Resources


Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA Panel

Gandhi RT, Bedimo R, Hoy JF, et al. JAMA. 2023;329(1):63-84.

Clinical Guidelines Program

New York State Department of Health AIDS Institute

Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV

US Department of Health and Human Services


Ward 86 long-acting injectable antiretroviral protocol

Getting to Zero San Francisco

HIV Drug Resistance Database

Stanford University

HIV Drug Interactions

University of Liverpool


AIDSMap Resources

NAM Publications

Resources for persons living with HIV

Centers for Disease Control and Prevention

HIV resources

National Institutes of Health


The Rapidly Changing Landscape of HIV Prevention in the Pharmacy Setting - Are You Ready?

This activity will focus on practical considerations for implementing preexposure prophylaxis (PrEP) services for HIV prevention in a pharmacy setting. Looking at PrEP access through a health equity lens, faculty will reflect on real-world patient perspectives and give strategies for how pharmacists can help efforts to end the HIV epidemic.

Providing PEP/PrEP in the Pharmacy Setting - A Comprehensive User Guide 2023

Pharmacists play an essential role in the initiative to end the HIV epidemic and, therefore, must stay up to date on guidelines and protocols for HIV preexposure and postexposure prophylaxis (PrEP and PEP, respectively). This comprehensive electronic/downloadable monograph was developed specifically to support the needs of pharmacists. Recently, the pharmacy scope of practice has expanded in a number of states in the US, and this continuing education activity provides the necessary clinical information for initiating and monitoring PrEP and PEP treatment in the pharmacy setting. This monograph provides the education pharmacists need to incorporate the Centers for Disease Control and Prevention (CDC) 2021 Updated PrEP Clinical Practice Guidelines into their daily practice. In addition, with 2.0 contact hour(s) (0.20 CEUs) from the Accreditation Council for Pharmacy Education, this monograph addresses all content necessary for pharmacists wishing to become PrEP and PEP providers in order to fulfill most state board of pharmacy training requirements.

Related activities
2.00 ACPE

Emerging Issues in HIV Management

Answers to Pharmacists’ Common Questions